• Vaccine Name: AdC68- rabies virus glycoprotein
• Target Pathogen: Rabies virus
• Target Disease: Rabies
• Vaccine Ontology ID: VO_0004630
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• G gene engineering:
  • Type: Recombinant vector construction
  • Description: A plasmid vector, termed pSG5rab.gp, that expresses the rabies virus glycoprotein under the control of an SV40 early promoter (Xiang et al., 1994).
  • Detailed Gene Information: Click Here.
• Vector:
  • Vector name:
  • VO vector ID: VO_0001087
  • Description: (Xiang et al., 2014)
• Preparation: Chimpanzee adenovirus (Ad) vector serotype SAd-V24, also termed AdC68, expressing the rabies virus glycoprotein (Xiang et al., 2014).
• Immunization Route: Intramuscular injection (i.m.)

Monkey Response

• Vaccination Protocol: An AdC vector control was used at 10^11 vp. A commercially available human diploid cell rabies vaccine (HDCV), used intramuscularly at the recommended dose for pre-exposure vaccination, was included. The AdC vector vaccine was only given once, and the HDCV was given three times on days −41, −27 and −20 in relation to the AdC vaccine (Xiang et al., 2014).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: Animals were challenged at 18 weeks after the last vaccine dose with ~10^6.4 (MICLD)50/ml as calculated via the Spearman–Kaerber method, of a virulent street strain of canine rabies virus (Xiang et al., 2014).
• Efficacy: The immunization resulted in sustained titers of rabies virus neutralizing antibodies and protection against a lethal rabies virus challenge infection in a non-human primate model (Xiang et al., 2014).